How HIV prevention drugs affect metabolism in healthy people
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests how certain HIV prevention drugs affect the body's metabolism (how it uses energy) in healthy people. It aims to understand side effects before these drugs are used more widely, which could help make future treatments safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are in good general health with no serious heart, liver, kidney, or lung problems.
- You are not currently infected with HIV or hepatitis.
- You have a body mass index (BMI) between 18.5 and 30, and your weight has been stable in the last 6 months.
- You do not smoke or use tobacco products.
- You are willing to use a barrier method of birth control (like condoms) or abstain from sex during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
This study tests whether switching your HIV medication to a combination called DOR/3TC/TDF can help with weight changes that started after taking another type of HIV drug (integrase inhibitor). It is for people who have gained weight unintentionally and want to see if a different medication helps manage it.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
Hear when a new Weight Gain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.